Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Interferons and Myeloproliferative Neoplasms (MPNs)

DECEMBER 07, 2016
Ruben Mesa, MD



Ruben Mesa, MD of the Mayo Clinic in Scottsdale Arizona talks about two new approaches to treating polycythemia vera, and essential thrombocythemia that use interferons.

References

Mascarenhas, JO, Prchal JT, Ranbaldi A, et al. Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. Presented at the 58th Annual ASH Meeting & Exposition; San Diego, CA; December 3-6, 2016. Abstract 479.
 
Gisslinger H, Klade C, Georgiev P, et al. Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients.Presented at the 58th Annual ASH Meeting & Exposition; San Diego, CA; December 3-6, 2016. Abstract 475.


Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.